Page last updated: 2024-09-05

symmetric dimethylarginine and Ventricular Dysfunction, Left

symmetric dimethylarginine has been researched along with Ventricular Dysfunction, Left in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atzler, D; Böger, RH; Chen, P; Chen, Y; Fassett, J; Guo, H; Hu, X; Kwak, D; Liu, X; Lu, Z; Schwedhelm, E; Wang, H; Xu, X; Yue, W; Zhang, P	1
Bode-Böger, SM; Bukowska, A; Ghanem, A; Goette, A; Hammwöhner, M; Klein, HU; Lehmann, HI; Martens-Lobenhoffer, J; Röhl, FW	1

Other Studies

2 other study(ies) available for symmetric dimethylarginine and Ventricular Dysfunction, Left

Article	Year
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction. Basic research in cardiology, 2017, 08-17, Volume: 112, Issue:5 Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Genetic Predisposition to Disease; Hypertrophy, Left Ventricular; Male; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide; Phenotype; Signal Transduction; Tyrosine; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2017
Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Defibrillators, Implantable; Follow-Up Studies; Humans; Male; Middle Aged; Nitric Oxide; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Dysfunction, Left	2011

Article

Year

Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.

Basic research in cardiology, 2017, 08-17, Volume: 112, Issue:5

Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Genetic Predisposition to Disease; Hypertrophy, Left Ventricular; Male; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide; Phenotype; Signal Transduction; Tyrosine; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2017

Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:10

Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Defibrillators, Implantable; Follow-Up Studies; Humans; Male; Middle Aged; Nitric Oxide; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Dysfunction, Left

2011